



sirona
biochem

INVESTOR PRESENTATION

March 2023

TSX-V: SBM

FSE: ZSB | OTC: SRBCF



FORWARD LOOKING STATEMENTS

Sirona Biochem cautions you that statements included in this presentation that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

TABLE OF CONTENTS

Investment Highlights 4	Facilities/M. Partners 16
Share Information 5	Technology 17
Business Model Strategy 6	Management 20
Business Model Success 7	Contact Us 22
Product Pipeline 8		
Worldwide IP Portfolio 11		
Milestones 12		
Our Next Big Thing 13		

INVESTMENT HIGHLIGHTS

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Through its wholly-owned French subsidiary TFChem, the Company specialises in stabilising carbohydrate molecules with the goal of improving efficacy and safety. Sirona Biochem's business model is to develop active ingredients that are then licensed out for up front payments, milestones and royalties.

- **Disruptive** proprietary carbohydrate-chemistry platform based on over 20 years of research and development.
- **In 2022, executed a global exclusive licensing deal** with **Allergan Aesthetics**, an **AbbVie** [NYSE: ABBV] company, for compound **TFC-1067**
- Research & discovery business model with **up-front, milestone and ongoing royalty payments** (including **upcoming royalties** on net sales generated by **AbbVie** product line based on licensed patented ingredients. Cooperating on additional products with AbbVie. **17 years** duration for TFC-1067 patents).
- **In December 2022, initiated a potentially transformative clinical trial for proprietary anti-aging compound, TFC-1326**
- Strong worldwide IP portfolio, including North America, European Union, and Asia.
- **Cosmetics** - Developing disruptive solutions for **anti-aging (\$271B USD)**, **cell preservation (\$7.5B USD)**, and **cellulite treatment (\$1.4B USD)**,
- **Pharmaceutical** - TFC-039, SGLT2 Inhibitor targeting human and animal diabetes. In advanced partnership talks for both indications.
 - Developing Anti-viral TBD compound for \$36B USD anti-viral market.
- State-of-the-art, multi-million dollar laboratory in France with top scientific team, strong **global manufacturing partners** for pharmaceutical (**Wanbang Pharma**, China) and cosmetics (**Wuxi AppTec**, China).

SHARE INFORMATION

TSX VENTURE
EXCHANGE **SBM**

OTCQX
EXCHANGE **SRBCF**

FRANKFURT STOCK
EXCHANGE **ZSB**

Shares owned by Insiders: 15%

FUNDAMENTAL DATA (CAD)

TSX-V	SBM
Shares Outstanding	251,911,526
Shares Fully Diluted	273,261,526
Share Price (CAD)	\$0.10
Market Cap	\$25,191,000
Year High	\$0.35
Year Low	\$0.085

**8.9M
SHARES
+ 5.2M
Options**

Dr. Howard V.
CEO - BOD Chairman



**10.4M
SHARES
+ 2.5M
Options**

Dr. Geraldine D.
Chief Scientific Officer



**1.23M
SHARES
+ 3.8M
Options**

Christopher H.
Chief Financial Officer



Our Management has
skin in the game

BUSINESS MODEL & STRATEGY

Sirona Biochem's strategy
is to **license or sell**
patented compounds to leading
global companies in return for
up-front fees, milestone fees
and ongoing royalty payments.

BUSINESS MODEL SUCCESS




Allergan Aesthetics,
an **AbbVie** [NYSE: ABBV] company, signed a
global exclusive licensing deal
with **Sirona Biochem**
for its library of breakthrough
compounds including **TFC-1067**

PRODUCT PIPELINE

Cosmetic Products



Pharmaceutical Products



Sirona Biochem has invested extensively in developing products to meet the needs of patients and industry partners. The compounds created through the company's **proprietary platform** go through rigorous tests and regulatory scrutiny to verify their safety and efficacy.

COSMETIC PRODUCTS

Therapeutic Area	Compound	Status
Skincare - Dark spot corrector (Rx & OTC)	TFC-1067 & family of dark spot correctors	<ul style="list-style-type: none"> • Exclusive global licensing deal with AbbVie for TFC-1067 signed
Cell Preservation & Repair (incl keloid & scar therapy)	Glycoprotein Library	<ul style="list-style-type: none"> • Ongoing lead determination
Skincare - Anti-Aging/ Anti-wrinkle	TFC-1326	<ul style="list-style-type: none"> • Clinical safety studies completed successfully with no adverse events • Clinical efficacy study currently ongoing and scheduled to complete in Spring 2023
Skincare - Cellulite Treatment	TBA	<ul style="list-style-type: none"> • Ongoing research & development

ESTIMATED MARKET SIZE

Skincare - Anti-Aging/Anti-wrinkle	\$271B USD by 2024
Skincare - Dark spot corrector (OTC & Rx)	\$8B USD
Cell Preservation & Repair (incl keloid & scar therapy)	\$7.5B USD
Skincare - Cellulite Treatment	\$1.45B USD

PHARMACEUTICAL PRODUCTS

Therapeutic Area	Compound	Status
Diabetes & Other (SGLT2 inhibitor)	TFC-039	<ul style="list-style-type: none"> • In due diligence & discussions with interested parties from the animal health sector • In due diligence & discussion for regional human health license
Anti-viral	TBD (from library)	<ul style="list-style-type: none"> • Entered into R&D collaboration with International Centre for Genetic Engineering and Biotechnology (ICGEB) • Completed first round of screening with library. 6 compounds showed efficacy. New generation being prepared for further screening .

ESTIMATED MARKET SIZE

Anti-Viral	\$36.98B USD
Diabetes & Other (SGLT2 inhibitor)	\$7.2B USD

Sirona Biochem is continually discovering new compounds and molecules, with the goal of advancing global medicine and health care.



sirona
biochem

WORLDWIDE IP PORTFOLIO

Sirona Biochem has a **strong IP portfolio**,
including a recently filed patent for its
breakthrough anti-aging compound **TFC-1326**,
managed by intellectual property law firm
Cabinet Regimbeau, Paris France



REGIMBEAU
Creative IP

MILESTONES

Milestones achieved in the last 12 months:

- ✓ Completed an exclusive, global license with AbbVie for TFC-1067
- ✓ Completed the terms of manufacturing and supply of TFC-1067 for AbbVie
- ✓ Completed a first round of testing the antiviral library with ICGEB
- ✓ Initiated scale-up and manufacturing of the anti-aging compound
- ✓ Completed a successful clinical safety study for TFC-1326, Sirona's proprietary anti-aging compound
- ✓ Initiated a 12-week clinical study for TFC-1326 with leading French aesthetics contract organization
- ✓ Added senior industry executive, Dr. Wolfgang Bieber, to the Advisory Board
- ✓ Awarded a financing partnership with the French Government
- ✓ Completed a significant patent extension for the anti-aging compounds

Sirona is working toward achieving the following milestones:

- Execute manufacturing and supply agreement with AbbVie
- Finalize an agreement for the SGLT2 inhibitor in animal health
- Finalize an agreement for the SGLT2 inhibitor for human health in new territory
- Complete the anti-aging clinical efficacy study for TFC-1326
- Begin partnership due diligence with companies for licensing TFC-1326
- Complete the second round of antiviral compound screening and advance to pre-clinical studies
- Advance and patent the SGLT2 inhibitor in various potential therapy areas
- Secure non-dilutive funding through grants
- File patents around novel compounds and therapy areas of interest

OUR NEXT BIG THING: Animal Health - TFC-039

INDUSTRY PROBLEM

It's estimated that **1.7 million cats** will develop **diabetes**. Treatment is needed to manage their condition, often requiring twice-daily injections.

Pet ownership rose sharply during the COVID-19 pandemic, pushing the animal health care market to more than **\$139 billion** and is predicted to grow at over **4.7%**

Sirona intends to be one of the first companies to bring a solution to the market.



INDUSTRY SOLUTION

Injections are inconvenient for owners and painful for pets. A **diabetes pill** made from **Sirona's TFC-039 compound** solves that problem and keeps pets healthy and happy.

Sirona has the solution to address this problem.

Top 5 Animal Pharmaceutical Companies and Revenue

Merck \$47.99B USD	Boehringer Ingelheim \$22B USD	Zoetis \$7.78B USD	Covertus \$4.33B USD	Elanco \$3.27B USD
------------------------------	--	------------------------------	--------------------------------	------------------------------



OUR NEXT BIG THING: Anti-Aging - TFC-1326

TFC-1326 & Compound Library


The anti-aging market is forecast to reach **\$271 Billion** by 2024, with anti-wrinkle accounting for **59.3%** of the total share.

Sirona recently filed a patent for its glycopeptides treatment, which rejuvenates and restores the skin's youthful glow by significantly increasing lipid synthesis.

Our next big breakthrough compound

TFC-1326 could become the industry's new go-to active ingredient to reverse skin aging by smoothing wrinkles and repairing skin damage. The technology could also be potentially applied to other cosmetic categories such as hair care, makeup and suncare.

Sirona has successfully completed the first clinical (safety) trial for TFC-1326. The clinical trial is currently underway in Europe and will complete Spring 2023.



FACILITIES/MANUFACTURING PARTNER

Sirona Biochem Laboratory

TFChem Laboratory, France

The 502-square-meter laboratory is located in Val de Reuil, France. This state-of-the-art facility is located in France's Cosmetic Valley, where the world's leading cosmetic companies conduct their research and development.

The award-winning team working at the facility specializes in developing fluorinated building blocks, which addresses the limitations usually associated with the application of carbohydrate-based molecules as active ingredients.

www.sironabiochem.com

Manufacturing Partner - TFC-1067

WuXi AppTec, China

WuXi AppTec provides a broad R&D and manufacturing services portfolio that enables the global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients.

The company has research, development, and manufacturing facilities in China, South Korea, the U.S., Germany, the UK, Switzerland, and Israel.

www.wuxiapptec.com

Manufacturing Partner - TFC-039

Wanbang Pharma, China

Wanbang Biopharma has established a domestic first-class R&D and manufacturing site in China for genetic engineering drugs of prokaryotic and eukaryotic cells.

The company employs more than 300 highly-educated professionals at its more than seven manufacturing sites across China, with a total area of more than 675,000 square meters.

www.chinawanbang.com

Anti-aging: TFC-1326 Laboratory

DIVA Laboratory, France

We're currently working with DIVA on anti-aging.

www.diva-expertise.com

TECHNOLOGY

Our world-class team is comprised of **award-winning scientists** who have worked for Fortune 500 companies such as **Sanofi, GSK** and **Bayer**.



Carbohydrate compounds have immense commercial potential.

- They are involved in many of our body's biological processes and are also used for development of active ingredients in pharmaceuticals and cosmetics

Examples of successful carbohydrate-based drugs are:

- Anti-viral medications such as **Tamiflu**, used for the treatment of Influenza A
 - Tamiflu: sales passed \$931 Million USD during swine flu epidemic (2019) -
- Blood thinners, such as: **Arixtra** and **Lovenox**, for the treatment of blood clots
 - Lovenox: sales of \$1.46 Billion USD (2018)

Geraldine Deliencourt-Godefroy, PhD

Founder, TFChem
Chief Scientific Officer

Our Technology has received more than **\$8M CAD** in grants from the French Government, including new financing to develop its advance chemistry process.

The challenges with carbohydrates are:


- Carbohydrates have complex syntheses requiring expert chemists
- Carbohydrates are unstable, causing lower efficacy or toxic by-products
- Carbohydrates have poor pharmacological properties

Sirona Biochem's
proprietary chemistry
increases the potential and
reduces the drawbacks
of carbohydrate molecules


- Sirona's Fluorination Chemistry Technology is **the solution** to **unstable carbohydrate molecules**.

- The chemistry strengthens the bonds of a carbohydrate molecule by strategically placing fluorine atoms.

Carbohydrate molecules
are unstable by nature



Sirona's technology
stabilizes carbohydrate
molecule



MANAGEMENT



Howard J. Verrico, MD

Founder, Sirona Biochem
CEO and Chairman of the Board

Dr. Verrico obtained his medical degree from the University of Toronto in 1985 and has been a member of the College of Physicians and Surgeons of British Columbia since July 1986. Dr. Verrico has extensive experience as a venture capitalist in the junior capital markets. He has acted as a venture capitalist for over 30 years, funding numerous start-ups and early-stage companies both in the private and public marketplace. He is the original founder of Sirona Biochem building the company by investing his personal funds starting in 2006. He has accumulated his large share position through personal share purchases. He currently is solely focused on the success and growth of SIRONA Biochem as it enters a stage of rapid growth.



Geraldine Deliencourt-Godefroy, PhD

Founder, TFChem
Chief Scientific Officer

Dr. Géraldine Deliencourt-Godefroy is an award-winning synthetic chemist and the founder of French-based biotechnology company TFChem. Since the acquisition of TFChem by Sirona Biochem in March 2011, Dr. Deliencourt-Godefroy has assumed the role of Chief Scientific Officer. Her scientific research in carbohydrate chemistry has led to the discovery of new drug families and the development of drug candidates for diabetes and obesity, cosmetic ingredients and biological adjuvants. Previous to founding TFChem, Dr. Deliencourt-Godefroy was a scientific leader at INSA (National Institute of Applied Sciences) in Rouen, France, where she developed a new technology for stabilized carbohydrates. Previous roles also include a post-doctoral position at the University College London and doctoral research at the Research Institute of Fine Organic Chemistry in Rouen, France. Dr. Deliencourt-Godefroy received a PhD and Masters in Organic Chemistry as well as her business degree from the University of France. She is the author of several publications and patents and is also the recipient of the acclaimed Francinov Research and Innovation Medal, French Ministry of Research Award and the French Senate Award.



Christopher Hopton, CPA, CGA

Chief Financial Officer

Christopher Hopton, Sirona Biochem's Chief Financial Officer, brings 28 years of expertise in financial management and operations. His extensive experience covers areas of financial planning, accounting policy and business process improvement. As a business investment and finance consultant, Mr. Hopton has worked with several public and privately-held companies. Most recently, Mr. Hopton was the Chief Financial Officer of Central Resources Corp., a junior mineral exploration company. Formerly, he held the position of Division Controller at Canadian Airlines where he was responsible for an annual operating budget of \$200M. Mr. Hopton was also involved in the restructuring of 360 Networks, a network communications company, which led to a buyout by Bell Canada. Mr. Hopton earned his Bachelor of Business Administration from Simon Fraser University in British Columbia, Canada and received his professional designation as a Certified General Accountant.



Michelle Seltenrich, MBA, BSc

Vice President - Operations

Michelle Seltenrich brings 21 years of expertise in publicly traded biotech companies. Her experience ranges from both academic and industrial R&D lab management to corporate mergers and acquisitions. Ms. Seltenrich was previously the Manager of Business Development at Forbes MediTech, a NASDAQ traded company, where she was responsible for international business development, in-licensing and M&A. She co-led a team in the successful acquisition of a U.S.-based biotech company. Ms. Seltenrich holds a BSc from the University of British Columbia and an MBA in Technology Management from Simon Fraser University.

CONTACT US

Sirona Biochem: Corporate Office
Parent Company - founded 2009



Sirona Biochem Corp.
c/o WeWork
595 Burrard Street,
Vancouver, BC
V7X 1L4

PHONE: +1.604.641.4466
EMAIL: info@sironabiochem.com
WEBSITE: www.sironabiochem.com

TFChem: Laboratory
Wholly Owned Subsidiary - acquired in 2011



TFChem
Voie de l'innovation
Pharma Parc II
27100 Val de Reuil
France

PHONE: +33(0)2.32.09.01.16w
FAX: +33(0)2.32.25.07.64
EMAIL: contact@tfchemistry.com



sirona
biochem

TSX-V: SBM
FSE: ZSB | OTC: SRBCF